SARASOTA, Fla. – Oragenics (NYSE:), Inc. (NYSE American: OGEN), a pharmaceutical company specializing in intranasal treatments for neurological disorders, announced today that CEO Kimberly Murphy has stepped down from her executive role as of February 12, 2024. Despite her resignation, Murphy will continue to contribute to the company as a member of the board of directors.
The transition comes with an assurance that Murphy’s departure is not due to any internal disputes regarding the company’s operations, policies, or practices. As part of the separation agreement, Murphy will receive the benefits stipulated under her employment contract for a separation without cause.
During this period of management change, Charlie Pope, Chairman of the Board, will take over as Executive Chairman on an interim basis. Additionally, Michael Redmond, the company’s President, has been appointed as Interim Principal Executive Officer, effective the same date.
Pope expressed gratitude for Murphy’s strategic leadership, particularly in relation to the company’s shift towards neurology assets. He anticipates her ongoing support will continue to positively influence the company.
Oragenics is known for its focus on developing nasal pharmaceuticals for neurological conditions, as well as tackling infectious diseases such as COVID-19 and its variants. The company’s product candidates include ONP-002, aimed at treating mild traumatic brain injuries (mTBI), and NT-CoV2-1, an intranasal vaccine candidate designed to prevent COVID-19, which is based on coronavirus spike protein research licensed from the National Institutes of Health (NIH) and the National Research Council of Canada (NRC).
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.